CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Participants in a new study who used GLP-1 drugs had a much lower cancer risk than those who had bariatric surgery.

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

Wellcare, which offers Medicare Advantage and Medicare Prescription ... Because it is approved to treat sleep apnea, ...

Larger studies are needed to confirm the findings, which offer the latest evidence that the medicines can do much more than ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.